It is a fact, you can't deny it when comparing ALA and CHM that the market applies different ways of valuing and that ALA has been / is still trying to get the iNKT-IND from the FDA to get started.
Nobody knows how well ALA's iNKT platform will perform and nobody knows how well CDH17 will perform. Both have huge potential in their fields of cancer treatment and if one that's not even having an IND gets valued about $140m and the other one already in the clinics and valued $0 then questions are warranted about Why?
I could actually launch a $15m t/o if I wanted today but it wouldn't be accepted and if, I would have to find another $20 to keep it going until I could sell it to a big pharma. That ship has sailed atm but still an option if the sp falls below 1c.
GLTA
CHM Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)